Raymond James Financial’s Xeris Biopharma Holdings XERS Stock Holding History

Raymond James Financial’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.61M	Sell	202,911 -5,362	-3%	-$34.2K	﹤0.01%	3666
2026 Q1	$1.21M	Sell	208,273 -3,146	-1%	-$20.9K	﹤0.01%	3727
2025 Q4	$1.66M	Buy	211,419 +6,206	+3%	+$48.8K	﹤0.01%	3416
2025 Q3	$1.67M	Sell	205,213 -3,933	-2%	-$26.1K	﹤0.01%	3307
2025 Q2	$977K	Buy	209,146 +28,830	+16%	+$132K	﹤0.01%	3607
2025 Q1	$990K	Buy	180,316 +167,166	+1,271%	+$675K	﹤0.01%	3501
2024 Q4	$44.6K	Buy	+13,150	New	+$42.3K	﹤0.01%	4622

Other funds holding XERS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Raymond James Financial's XERS Position: Q2 2026 in Review

Raymond James Financial reduced its Xeris Biopharma Holdings (XERS) stake by 2.6% in Q2 2026, selling an estimated $34.2K and leaving 202,911 shares worth $1.61M. The position accounts for ﹤0.01% of the portfolio, ranked #3666.

Raymond James Financial first reported a position in XERS in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.67M in Q3 2025. 240 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

Raymond James Financial held 202,911 shares of Xeris Biopharma Holdings worth $1.61M as of Q2 2026.
Raymond James Financial sold 5,362 Xeris Biopharma Holdings shares in Q2 2026, an estimated $34.2K.
Xeris Biopharma Holdings made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3666 holding.
Raymond James Financial first reported a position in Xeris Biopharma Holdings in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Xeris Biopharma Holdings position peaked at $1.67M in Q3 2025.
240 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.